Top

Published in:

01-01-2013

Polymorphisms in Factor II and Factor V thrombophilia genes among Circassians in Jordan

Authors: R. Dajani, A. Arafat, N. Hakooz, Z. Al-Abbadi, Al-Motassem Yousef, M. El Khateeb, F. Quadan

Published in: Journal of Thrombosis and Thrombolysis | Issue 1/2013

Abstract

Thrombosis is a major cause of morbidity and mortality worldwide. Genetic factors are one component of thrombosis. We studied the prevalence of two mutations that are known risk factors in the pathogenesis of arterial and venous thrombosis in the genetically isolated Circassian population in Jordan. Factor II G20210A and Factor V Leiden single nucleotide polymorphisms were analysed by polymerase chain reaction and restriction fragment length polymorphism method in 104 random unrelated subjects from the Circassian population in Jordan. The prevalence rates among the Circassian population in Jordan for Factor II G20210A was 12.2 % and for Factor V Leiden was 7.7 %. We have shown that the population is in Hardy–Weinberg equilibrium and that the prevalences of both mutations are within the range of other ethnic groups. This is the first study to describe Circassian health related genetic characteristics in Jordan. Such population-based studies will contribute to understanding the interaction between genetic and environmental risk factors. It will remain to be seen whether carriers of Factor II G20210A and Factor V Leiden are more likely to develop thrombosis. This issue should be studied in the future to determine the need for screening of these mutations particularly in thrombophilia patients.

Khan S, Dickerman JD (2006) Hereditary thrombophilia. Thromb J 4:15. doi:10.1186/1477-9560-4-15 PubMedCrossRef

Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, Chandy M, Dahlback B, Ginter EK, Miletich JP, Rosendaal FR, Seligsohn U (1996) Inherited thrombophilia: Part 1. Thromb Haemost 76(5):651–662PubMed

Segers K, Dahlback B, Nicolaes GA (2007) Coagulation factor V and thrombophilia: background and mechanisms. Thromb Haemost 98(3):530–542PubMed

Rosendaal FR (1999) Venous thrombosis: a multicausal disease. Lancet 353(9159):1167–1173PubMedCrossRef

Dahlback B, Carlsson M, Svensson PJ (1993) Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 90(3):1004–1008PubMedCrossRef

Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369(6475):64–67PubMedCrossRef

Bauduer F, Lacombe D (2005) Factor V Leiden, prothrombin 20210A, methylenetetrahydrofolate reductase 677T, and population genetics. Mol Genet Metab 86(1–2):91–99PubMedCrossRef

Poort SR, Rosendaal FR, Reitsma PH, Bertina RM (1996) A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88(10):3698–3703PubMed

Nasidze I, Ling EY, Quinque D, Dupanloup I, Cordaux R, Rychkov S, Naumova O, Zhukova O, Sarraf-Zadegan N, Naderi GA, Asgary S, Sardas S, Farhud DD, Sarkisian T, Asadov C, Kerimov A, Stoneking M (2004) Mitochondrial DNA and Y-chromosome variation in the Caucasus. Ann Hum Genet 68(Pt 3):205–221PubMedCrossRef

10.

Barbujani G, Nasidze IS, Whitehead GN (1994) Genetic diversity in the Caucasus. Hum Biol 66(4):639–668PubMed

11.

Bulayeva KB (2006) Overview of genetic-epidemiological studies in ethnically and demographically diverse isolates of Dagestan, Northern Caucasus, Russia. Croat Med J 47(4):641–648PubMed

12.

Shishani K, Dajani R, Khader Y (2011) Hypertension risk assessment in the largest ethnic groups in Jordan. J Immigr Minor Health. doi:10.1007/s10903-011-9533-y PubMed

13.

Falik-Zaccai TC, Haron Y, Eilat D, Harash B, Golinker E, Hussein O, Eisikovits R, Borochowitz Z, Linn S (2003) Coronary heart disease among Circassians in Israel is not associated with mutations in thrombophilia genes. Hum Biol 75(1):57–68PubMedCrossRef

14.

Bortolin S, Black M, Modi H, Boszko I, Kobler D, Fieldhouse D, Lopes E, Lacroix JM, Grimwood R, Wells P, Janeczko R, Zastawny R (2004) Analytical validation of the tag-it high-throughput microsphere-based universal array genotyping platform: application to the multiplex detection of a panel of thrombophilia-associated single-nucleotide polymorphisms. Clin Chem 50(11):2028–2036PubMedCrossRef

15.

Gupta N, Khan F, Tripathi M, Singh VP, Tewari S, Ramesh V, Sinha N, Agrawal S (2003) Absence of factor V Leiden (G1691A) mutation, FII G20210A allele in coronary artery disease in North India. Indian J Med Sci 57(12):535–542PubMed

16.

Doggen CJ, Cats VM, Bertina RM, Rosendaal FR (1998) Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 97(11):1037–1041PubMedCrossRef

17.

Franco RF, Trip MD, ten Cate H, van den Ende A, Prins MH, Kastelein JJ, Reitsma PH (1999) The 20210 G→A mutation in the 3′-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease. Br J Haematol 104(1):50–54PubMedCrossRef

18.

Russo C, Girelli D, Olivieri O, Guarini P, Manzato F, Pizzolo F, Zaia B, Mazzucco A, Corrocher R (2001) G20210A prothrombin gene polymorphism and prothrombin activity in subjects with or without angiographically documented coronary artery disease. Circulation 103(20):2436–2440PubMedCrossRef

19.

Antoniadi T, Hatzis T, Kroupis C, Economou-Petersen E, Petersen MB (1999) Prevalence of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations in a Greek population of blood donors. Am J Hematol 61(4):265–267PubMedCrossRef

20.

Eid SS, Rihani G (2004) Prevalence of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations in 200 healthy Jordanians. Clin Lab Sci 17(4):200–202PubMed

21.

Bouaziz-Borgi L, Almawi WY, Mtiraoui N, Nsiri B, Keleshian SH, Kreidy R, Louzir B, Hezard N, Mahjoub T (2006) Distinct association of factor V-Leiden and prothrombin G20210A mutations with deep venous thrombosis in Tunisia and Lebanon. Am J Hematol 81(8):641–643. doi:10.1002/ajh.20582 PubMedCrossRef

22.

Almawi WY, Keleshian SH, Borgi L, Fawaz NA, Abboud N, Mtiraoui N, Mahjoub T (2005) Varied prevalence of factor V G1691A (Leiden) and prothrombin G20210A single nucleotide polymorphisms among Arabs. J Thromb Thrombolysis 20(3):163–168PubMedCrossRef

23.

Abu-Amero KK, Wyngaard CA, Kambouris M, Dzimiri N (2002) Prevalence of the 20210 G→A prothrombin variant and its association with coronary artery disease in a Middle Eastern Arab population. Arch Pathol Lab Med 126(9):1087–1090PubMed

24.

Zoller B, Norlund L, Leksell H, Nilsson JE, von Schenck H, Rosen U, Jepsson JO, Dahlback B (1996) High prevalence of the FVR506Q mutation causing APC resistance in a region of southern Sweden with a high incidence of venous thrombosis. Thromb Res 83(6):475–477PubMedCrossRef

25.

Awidi A, Shannak M, Bseiso A, Kailani MA, Kailani MA, Omar N, Anshasi B, Sakarneh N (1999) High prevalence of factor V Leiden in healthy Jordanian Arabs. Thromb Haemost 81(4):582–584PubMed

26.

Irani-Hakime N, Tamim H, Kreidy R, Almawi WY (2000) The prevalence of factor V R506Q mutation-Leiden among apparently healthy Lebanese. Am J Hematol 65(1):45–49PubMedCrossRef

27.

Jaber L, Shohat M, Halpern GJ (1996) Demographic characteristics of the Israeli Arab community in connection with consanguinity. Isr J Med Sci 32(12):1286–1289PubMed

28.

Lucotte G, Mercier G (2001) Population genetics of factor V Leiden in Europe. Blood Cells Mol Dis 27(2):362–367PubMedCrossRef

29.

Li JZ, Absher DM, Tang H, Southwick AM, Casto AM, Ramachandran S, Cann HM, Barsh GS, Feldman M, Cavalli-Sforza LL, Myers RM (2008) Worldwide human relationships inferred from genome-wide patterns of variation. Science 319(5866):1100–1104. doi:10.1126/science.1153717 PubMedCrossRef

30.

Derenko M, Malyarchuk B, Grzybowski T, Denisova G, Dambueva I, Perkova M, Dorzhu C, Luzina F, Lee HK, Vanecek T, Villems R, Zakharov I (2007) Phylogeographic analysis of mitochondrial DNA in northern Asian populations. Am J Hum Genet 81(5):1025–1041. doi:10.1086/522933 PubMedCrossRef

31.

Macaulay V, Richards M, Hickey E, Vega E, Cruciani F, Guida V, Scozzari R, Bonne-Tamir B, Sykes B, Torroni A (1999) The emerging tree of West Eurasian mtDNAs: a synthesis of control-region sequences and RFLPs. Am J Hum Genet 64(1):232–249. doi:10.1086/302204 PubMedCrossRef

32.

Rosendaal FR, Doggen CJ, Zivelin A, Arruda VR, Aiach M, Siscovick DS, Hillarp A, Watzke HH, Bernardi F, Cumming AM, Preston FE, Reitsma PH (1998) Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 79(4):706–708PubMed

33.

Ridker PM, Hennekens CH, Miletich JP (1999) G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation 99(8):999–1004PubMedCrossRef

34.

Tanis BC, Bloemenkamp DG, van den Bosch MA, Kemmeren JM, Algra A, van de Graaf Y, Rosendaal FR (2003) Prothrombotic coagulation defects and cardiovascular risk factors in young women with acute myocardial infarction. Br J Haematol 122(3):471–478PubMedCrossRef

35.

Rahimi Z, Vaisi-Raygani A, Mozafari H, Kharrazi H, Rezaei M, Nagel RL (2008) Prevalence of factor V Leiden (G1691A) and prothrombin (G20210A) among Kurdish population from Western Iran. J Thromb Thrombolysis 25(3):280–283PubMedCrossRef

36.

Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH (1995) High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 85(6):1504–1508PubMed

37.

Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP (1995) Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 332(14):912–917. doi:10.1056/NEJM199504063321403 PubMedCrossRef

38.

Ridker PM, Miletich JP, Hennekens CH, Buring JE (1997) Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA 277(16):1305–1307PubMedCrossRef

39.

Mansourati J, Da Costa A, Munier S, Mercier B, Tardy B, Ferec C, Isaaz K, Blanc JJ (2000) Prevalence of factor V Leiden in patients with myocardial infarction and normal coronary angiography. Thromb Haemost 83(6):822–825PubMed

40.

Juul K, Tybjaerg-Hansen A, Steffensen R, Kofoed S, Jensen G, Nordestgaard BG (2002) Factor V Leiden: the Copenhagen city heart study and 2 meta-analyses. Blood 100(1):3–10. doi:10.1182/blood-2002-01-0111 PubMedCrossRef

41.

Schroder W, Koesling M, Wulff K, Wehnert M, Herrmann FH (1996) Large-scale screening for factor V Leiden mutation in a north-eastern German population. Haemostasis 26(5):233–236PubMed

42.

Pecheniuk NM, Marsh NA, Walsh TP, Dale JL (1997) Use of first nucleotide change technology to determine the frequency of factor V Leiden in a population of Australian blood donors. Blood Coagul Fibrinolysis 8(8):491–495PubMedCrossRef

43.

Garcia-Gala JM, Alvarez V, Pinto CR, Soto I, Urgelles MF, Menendez MJ, Carracedo C, Lopez-Larrea C, Coto E (1997) Factor V Leiden (R506Q) and risk of venous thromboembolism: a case–control study based on the Spanish population. Clin Genet 52(4):206–210PubMedCrossRef

44.

Pepe G, Rickards O, Vanegas OC, Brunelli T, Gori AM, Giusti B, Attanasio M, Prisco D, Gensini GF, Abbate R (1997) Prevalence of factor V Leiden mutation in non-European populations. Thromb Haemost 77(2):329–331PubMed

45.

Takamiya O, Ishida F, Kodaira H, Kitano K (1995) APC-resistance and Mnl I genotype (Gln 506) of coagulation factor V are rare in Japanese population. Thromb Haemost 74(3):996PubMed

46.

Kim YW, Yoon KY, Park S, Shim YS, Cho HI, Park SS (1997) Absence of factor V Leiden mutation in Koreans. Thromb Res 86(2):181–182PubMedCrossRef

47.

Rees DC, Cox M, Clegg JB (1995) World distribution of factor V Leiden. Lancet 346(8983):1133–1134PubMedCrossRef

48.

Dajani R, Fatahallah R, Dajani A, Al-Shboul M, Khader Y (2012) Prevalence of coagulation factor 11 G20210A and factor V G1691A Leiden polymorphisms in Chechens, a genetically isolated population in Jordan. Mol Biol Rep. doi:10.1007/s11033-012-1785-7

Title: Polymorphisms in Factor II and Factor V thrombophilia genes among Circassians in Jordan
Authors: R. Dajani
A. Arafat
N. Hakooz
Z. Al-Abbadi
Al-Motassem Yousef
M. El Khateeb
F. Quadan
Publication date: 01-01-2013
Publisher: Springer US
Published in: Journal of Thrombosis and Thrombolysis / Issue 1/2013
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-012-0772-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

Pharmacogenetic tests could be helpful in predicting of VKA maintenance dose in elderly patients at treatment initiation

Erratum to: Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin

PAR-1 antagonists: current state of evidence

Perioperative assessment of platelet function by Thromboelastograph® Platelet Mapping™ in cardiovascular patients undergoing non-cardiac surgery

Association of COX-2 rs20417 with aspirin resistance

Risk-assessment models for predicting venous thromboembolism among hospitalized non-surgical patients: a systematic review

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials